Andrew J. Aguirre

Abstract PR011: Digenic CRISPR screening identifies novel KRAS/FGFR combination therapies for pancreatic cancer

Adaptive signaling remains a major barrier to durable responses with targeted therapy in pancreatic ductal adenocarcinoma (PDAC), where oncogenic KRAS drives the vast majority of tumors. To identify clinically actionable resistance nodes, we developed RAS+, a digenic CRISPR knockout library that systematically interr...

Tumor-tropic E. coli engineered as living T and NK cell engagers

Cancers modulate processing and presentation of p53 neoantigens to evade T cell detection.

TP53 mutations occur early in malignant transformation as truncal events in tumor evolution and are therefore generally present in all descendant tumor cells, creating an immunological vulnerability. Here, we examined the immunogenicity and antigenicity of p53 neoantigens emerging from these truncal mutations. Comprehe...

A compendium of next-generation patient-derived models for diverse cancers

The development of new therapeutics and the validation of pathogenetic cancer mechanisms require representative laboratory models1,2. However, existing collections represent only a fraction of the diversity observed in human cancer2, 3–4. Recent technologies have enabled efficient in vitro model derivation (for example...